A 2026 study published in The Lancet suggests that tirzepatide, a dual GLP-1 and GIP receptor agonist already approved for treatment of diabetes and obesity, could be an effective tool for fighting alcohol use disorder (AUD)
SW, LG, YW and CW performed the data analysis and interpretation
A simple heads-up is enough: "Energy is low today." "My stomach is a little off." "I changed my dose this week." "I haven't eaten much today." That's all your coach needs to make the workout fit the day
Eating the right kinds of meals can help to reduce common side effects, such as nausea or constipation, which some people experience when their body is adjusting to a GLP-1 medication
Center SA, Warner KL, Randolph JF, Sunvold GD, Vickers JR: Influence of dietary supplementation with (L)-carnitine on metabolic rate, fatty acid oxidation, body condition, and weight loss in overweight cats
This isn't just paperwork